Trial By Error: The Surprising New BMJ Best Practice Guide

This report puts the National Institute for Health and Care Exellence (NICE) to shame. NICE develops clinical guidelines that are widely followed in the U.K, and in other countries as well. A NICE surveillance team had the opportunity to review the same recent literature available to Dr. Baraniuk and recommended in June that the agency should make no changes to its 2007 guidance—which of course highlights CBT and GET as effective treatments. In September, after patient organizations expressed overwhelming opposition to this recommendation, NICE rejected it and announced that the 2007 guidance would instead undergo a complete overhaul. The new NICE committee that will be tasked with developing fresh guidelines should thank Dr. Baraniuk for providing them with a pretty good road map. It would be fascinating to learn the back-story of this report. What did the BMJ Publishing Group expect when Dr. Baraniuk took on this assignment? What did Professor White really think during his peer-review of a document that inflicts such serious damage on his legacy? Do Professor White and his colleagues finally recognize that the larger scientific community has rejected their flawed trial and that their long reign over this domain of research is finally coming to an end? It is too soon to tell whether Dr. Baraniuk’s report will turn out to be an inflection point in the British understanding and treatment of ME/CFS. Old prejudices (and paradigms) die hard, and the PACE-influenced U.K. medic...
Source: virology blog - Category: Virology Authors: Tags: Uncategorized Source Type: blogs